Liver cirrhosis can have different underlying causes, making accurate diagnosis essential for choosing the right treatment. A study explores how IgG, IgA, and IgM immunoglobulin levels can help distinguish between these causes and support diagnosis without the need for a liver biopsy.
Viral load and transaminase levels are important indicators for assessing the prognosis of chronic hepatitis B. A study published in The Lancet found that an HBV DNA level above 2,000 IU/mL and elevated transaminases are associated with a higher risk of advanced liver disease. These markers can help guide patient monitoring and individualized treatment decisions.
A study published in The New England Journal of Medicine shows that Bepirovirsen significantly increases the likelihood of achieving a functional cure for chronic hepatitis B.
A study suggests GST-HG141 may become an effective new hepatitis B treatment for patients with incomplete response to current antiviral therapies.
A study shows spironolactone reduces fatty liver risk in patients with hypertension, lowering liver fat accumulation and slowing fibrosis progression.
Autoimmune hepatitis incidence has increased notably in older adults, with higher prevalence and better treatment response, often presenting with milder symptoms.
Orforglipron, an oral GLP-1 small molecule, shows significant weight loss results and may become an alternative to injectable drugs like Ozempic or Wegovy.
Hydronidone has demonstrated significant reversal of liver fibrosis in patients with chronic hepatitis B, offering a potential new therapeutic option.
HU6 is a novel oral drug that reduces liver fat and body weight through controlled metabolic acceleration, showing promising results in clinical trials compared to placebo.
A large study shows that daily alcohol consumption, even in small amounts, worsens liver fibrosis in patients with metabolic liver disease.